[Management of dyslipidemia in HIV-infected patients].
aba@isarpraxis.de
Anna-Maria
AM
Moog
Werner
W
Becker
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology*; D009203:Myocardial Infarction / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors
D019380:Anti-HIV Agents; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol